LDL cholesterol: The current target of therapy
==============================================

Epidemiologic data from populations with and without coronary artery disease (CAD) have highlighted the importance of reducing low density lipoprotein cholesterol (LDL-C) in preventing both new-onset CAD and recurrent ischemic events ([@b103], 1984b, 1984a; [@b90]; [@b112]; [@b109]). Indeed, there is a log-linear relationship between LDL-C and CAD risk, and this relationship holds true at low LDL-C levels ([@b46]). Not surprisingly, LDL-C was identified by the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) reports as being the primary focus of cholesterol-reducing therapy and successive NCEP ATP reports have recommended successively lower LDL-C goals for high risk patients ([@b4]). However, the ATP-III report acknowledges that when serum triglycerides (TG) are \>200 mg/dl, increased remnant atherogenic lipoproteins greatly heighten risk predicted by LDL-C and this is associated with a substantially elevated very low density lipoprotein cholesterol (VLDL-C) ([@b4]). VLDL-C is not accounted for by the calculation of LDL-C in standard lipid panels. When serum TG is \<150 mg/dl, VLDL-C is usually \<30 mg/dl and hence VLDL-C arguably makes a small contribution to the atherogenic cholesterol pool (1979). However, for patients with TG\>200 mg/dl, non high density lipoprotein cholesterol (non-HDL-C) is identified as a secondary target of therapy with the target being \<30 mg/dl greater than the LDL-C target ([@b4]). Non-HDL-C is simply calculated from a standard lipid panel as total cholesterol (TC) minus HDL-C and accounts for LDL-C, VLDL-C, IDL-C, chylomicron remnants, and lipoprotein a. Non-HDL-C is highly correlated with apolipoprotein B (apoB) and therefore provides a more accurate measure of the cholesterol in atherogenic particles ([@b4]). While non-HDL-C is highly correlated with LDL-C (r = 0.94), at TG \>150 mg/dl, non-HDL-C becomes displaced upwards and the correlation weakens ([@b1]). Since hypertriglyceridemia affects 16% of the American population and 37% of diabetics ([@b95]), non-HDL-C may be a more appropriate primary target of therapy since LDL-C may be less reliable for risk prediction in a sizeable proportion of the population ([@b83]). Moreover, non-HDL-C may be a superior predictor of CAD events regardless of TG; a 5794 person cohort from the Framingham study showed non-HDL-C to be a superior predictor of CAD events compared with LDL-C and also showed VLDL-C to predict CAD events after adjusting for LDL-C in patients with TG \>200 mg/dl and in patients with TG \<200 mg/dl ([@b65]). Further, VLDL-C correlated poorly (r = 0.08) with LDL-C and an advantage of a non-HDL-C target is that it incorporates both LDL-C and VLDL-C. The triglyceride-rich lipoproteins which are not accounted for by LDL-C measurement have been associated with both increased angiographic progression of CAD and hard clinical end points ([@b82]; [@b70]; [@b91]). Further, non-HDL-C is inversely correlated to HDL-C in adults and children ([@b42], [@b101]). The need to change the primary target of therapy is arguably more pressing given the increasing prevalence of obesity, diabetes, the metabolic syndrome and hypertriglyceridemia; this paper proposes that non-HDL-C should be the primary target of therapy for all patients.

Diabetes, obesity, metabolic syndrome, atherogenic dyslipidemia and cardiovascular events
=========================================================================================

Recent data from the Framingham Offspring study have shown that the incidence of type 2 diabetes in the 1990s has doubled when compared to the 1970s, with most of the absolute increase in diabetes incidence occurring in the obese as determined by body mass index (BMI) of greater than 30 ([@b37]). This finding is concordant with secular trends found in the San Antonio Heart Study from 1987--1996 ([@b18]). Data collected from the Framingham cohort over 5 decades has shown that the burden of cardiovascular disease is increasingly attributable to diabetes mellitus ([@b36]). Some studies have shown diabetics without previous myocardial infarction to harbor the same risk of cardiovascular death and myocardial infarction as non-diabetic patients with previous myocardial infarction ([@b48]). However, this high risk of cardiovascular events in diabetics depends on co-existing cardiovascular risk factors as shown in the Strong Heart Study and the Multiple Risk Factor Intervention Trial (MRFIT) ([@b107]; [@b50]). Similarly, in an National Health and Nutrition Examination Survey (NHANES III) analysis, patients with diabetes but without the metabolic syndrome (only 14% of diabetics) did not have an increased risk of CAD ([@b2]). The diagnosis of the metabolic syndrome (criteria in [Table 1](#tbl1){ref-type="table"}) describes the clustering of central adiposity with impaired fasting glucose, elevated blood pressure, high TG, and low HDL-C ([@b43]; [@b115]; [@b84]) and, like diabetes, is associated with an increased risk of cardiovascular events ([@b13]; [@b60]; [@b71]; [@b19]; [@b79]). Individual components of the metabolic syndrome, like impaired fasting glucose have been shown to be independently associated with an increased risk of cardiovascular death ([@b6]). This clustering of risk factors is ultimately driven by visceral adiposity which can be quantified by waist circumference measurements or imaging studies which, with insulin resistance, drives the increased risk of cardiovascular events ([@b20]; [@b45]; [@b115]; [@b12]; [@b44]). Since obesity, metabolic syndrome, and diabetes are common conditions, treating the ensuing increased risk of cardiovascular events is of great public health significance.

###### 

ATP III and IDF Definitions of the metabolic syndrome ([@b4]; [@b63]).

  IDF Criteria (first criterion compulsory plus any additional 2)                                                              ATP III Criteria (3/5 required for diagnosis)
  ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------
  Waist circumference \>94 cm in Europid males or \> 80 cm in Europid females (with ethnic-specific values for other groups)   Waist circumference \>102 cm in males or \> 88 cm in females
  Triglycerides \>150 mg/dl or specific treatment for lipid abnormality                                                        Triglycerides \>150 mg/dl
  HDL cholesterol \<40 mg/dl in a male or \<50 mg/dl in a female or specific treatment for lipid abnormality                   HDL cholesterol \<40 mg/dl in a male or \<50 mg/dl in a female
  Blood pressure \>130/85 or antihypertensive medications                                                                      Blood pressure \>130/85 or anti-hypertensive medications
  Fasting glucose \>100 mg/dl or previously diagnosed type 2 diabetes                                                          Fasting glucose \>110 mg/dl

NHANES data has shown roughly one third of American adults over the age of 20 to be obese, 9.3% of Americans to be diabetic with another 26% having impaired fasting glucose, and a nearly double prevalence of diabetes in minorities ([@b24]; [@b80]). The metabolic syndrome is similarly prevalent and affects roughly a quarter of Americans above the age of 20 ([@b32]) and 44% of Americans over the age of 50 ([@b2]). The purpose of this paper is to discuss the alterations in lipid parameters that occur with obesity and to argue that non-HDL-C is a more appropriate target for lipid-lowering therapy than LDL-C given that, as societies, we are becoming fatter and more diabetes-prone ([@b30]; [@b33]). This is especially topical as absolute risk for cardiovascular events in primary prevention and secondary prevention increasingly overlap, largely driven by the increase in obesity, metabolic syndrome and diabetes in the primary prevention setting ([@b107]; [@b51], [@b50]; [@b4]).

The lipid profile of obesity
============================

In an analysis of men enrolled in the NHANES II database, increasing BMI was associated with higher TC, TG, and non-HDL-C, but with lower HDL-C. In middle-aged and older men, LDL-C did not vary with BMI ([@b27]). Indeed, while excess body weight has been consistently associated with increases in TG, VLDL-C, TC, and decreased HDL-C, the effects of body weight on LDL-C have been variable ([@b34]; [@b55]; [@b73]; [@b28]). Further, while TC and LDL-C generally correlate on a population level, this correlation weakens at higher body weights where VLDL-C makes a larger contribution to TC ([@b110]). Similarly, obese children have higher TC and TG than non-obese children with no significant difference in LDL-C ([@b38]). In a pediatric population, non-HDL-C correlated with BMI and with waist circumference while LDL-C did not ([@b101]). Such observations in children are highly relevant to preventative cardiologists since children with higher non-HDL-C are more likely as adults to have high non-HDL-C, to be obese adults, to have hypertriglyceridemia, impaired fasting glucose, hyperinsulinemia, and low HDL-C while LDL-C levels in children are not similarly predictive ([@b100]). An analysis of adults in the NHANES III dataset corroborated these findings in children and showed non-HDL-C to be a significantly stronger correlate with BMI than LDL-C ([@b40]). Similarly, the accumulation of visceral adipose tissue which drives the metabolic syndrome and diabetes is associated with the lipoprotein profile of obesity which includes a normal LDL-C despite elevated cardiovascular risk ([@b114]). Intra-abdominal fat, quantified with computed tomography scanning, correlates with insulin resistance and patients with high amounts of intra-abdominal fat and greater degrees of insulin resistance have elevated TC, TG, ApoB, VLDL-C, and less HDL-C ([@b78]). Similarly, in the Framingham cohort, TC and TG were shown to correlate positively with visceral adipose tissue while HDL-C correlated negatively ([@b36]). Determination of LDL-C is not informative of these changes in lipid parameters that are concomitants of the accumulation of visceral fat.

The NHANES III data set suggests that at least 13 million US adults with CAD or CAD risk equivalents have an LDL-C of \<130 mg/dl while 5 million US adults have an LDL-C \<100 mg/dl ([@b21]) and hence may not qualify for drug therapy based on current ATP III guidelines. Further, most patients who develop ischemic heart disease have LDL-C levels in the 'normal' range ([@b102]) and a cross-sectional analysis from the Framingham cohort showed that men with CAD have LDL-C that is no different from those without CAD ([@b93]). Importantly, non-HDL-C was significantly higher in CAD than in control subjects ([@b93]) and hence the adoption of non-HDL-C as a primary target of therapy may lead to appropriate intensification of therapy. From a pathophysiologic perspective, non-HDL-C better reflects the increased cardiovascular risk associated with high apoB levels and small LDL particle size which are hallmarks of obesity.

Cholesterol metabolism in obesity and insulin resistance
========================================================

Lipoprotein kinetic studies show that the liver overproduces apoB and triglycerides in the VLDL fraction in obesity and the two drivers of this process are hypertriglyceridemia and insulin resistance ([@b72]; [@b7]; [@b22]). Further, obesity is associated with an increase in cholesterol synthesis and a decrease in intestinal absorption ([@b77]; [@b75]; [@b58]; [@b49]) and these variables are responsive to weight loss ([@b75]). In 2000, Miettinen suggested that low cholesterol absorption is a component of the metabolic syndrome ([@b96]). Not surprisingly, the changes in cholesterol metabolism in type 2 diabetics are similar to those seen in obese individuals; namely a lowered cholesterol absorption efficiency, decreased absorption marker ratios ([@b15]; [@b47]; [@b96], [@b97]) and increased levels of synthesis markers and cholesterol synthesis determined with sterol balance ([@b9]; [@b47]; [@b97]; [@b76]; [@b49]). The significance of these observations is that VLDL-C is an independent predictor of CAD events, after adjustment for LDL-C ([@b65]). Conversely, weight loss has been shown to produce consistent reductions in VLDL-C, TG levels and increases in HDL-C with variable effects on LDL-C ([@b16]; [@b111]; [@b31]; [@b113]). Measuring non-HDL-C includes the cholesterol in the VLDL fraction and therefore better capitulates this shift in phenotype to increased cholesterol synthesis with obesity whereas considering LDL-C alone is uninformative. Higher BMI is associated with increases in non-HDL-C, TC, VLDL-C, and apoB, reflecting higher hepatic synthesis of VLDL and an increased number of atherogenic particles ([@b61]). In contrast to non-HDL-C, LDL-C often remains unchanged in obesity and insulin resistance.

Non-HDL-C correlates better than LDL-C with apoB
================================================

Patients with the metabolic syndrome have an increased concentration of apoB and TC despite no difference in LDL-C compared with individuals without the metabolic syndrome ([@b53]). In this context, it is hardly surprising that apoB concentrations added to the predictive value of LDL-C in the Quebec Heart Study which was a prospective cohort followed for 13 years ([@b104]). Further, there was poor concordance between LDL-C and apoB values in this population, especially amongst the majority of the population in the middle quintiles of LDL-C. Non-HLD-C was a superior correlate to ApoB than LDL-C and those with disproportionately elevated apoB were those with higher BMI, higher TG, lower HDL-C, and smaller LDL particles, ie, features of the metabolic syndrome ([@b99]). The superior correlation of non-HDL-C with apoB compared to LDL-C is also illustrated by data from the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS) investigators. Non-HDL-C correlated better with apoB than LDL-C, especially in patients with CAD and non-HDL-C correlated with ApoB (r \> 0.90) across all TG strata while the correlation between LDL-C and apoB deteriorated as TG increased (r = 0.81 if TG \> 250 mg/dl) and was poorer in those with CAD (r = 0.81) than in lower risk patients without CAD (r = 0.86) ([@b5]). The measurement of apoB levels for cardiovascular risk prognostication has its supporters, especially in Canada ([@b41]) and is the 'gold standard' for cardiovascular risk management according to its proponents ([@b108]; [@b98]). ApoB assays have been standardized and several experts have championed the inclusion of apoB measurement in treatment guidelines ([@b8]). While non-HDL-C correlates well with apoB, its concordance has been relatively poorer ([@b8]). However, the prognostic utility of non-HDL-C in predicting the hard clinical endpoint (discussed below) is perhaps the primary consideration for the clinician. Moreover, on a worldwide basis, the standard lipid panel remains the mainstay of lipid assessment and the adoption of non-HDL-C as the primary therapeutic target would not require clinician re-education to the same extent that adoption of apoB as a therapeutic target would. As such, to replace LDL-C as the primary therapeutic target with non-HDL-C instead of apoB may be based more on pragmatism than evidence per se.

Non-HDL-C correlates better than LDL-C with small dense LDL particles
=====================================================================

As well as being associated with increased apoB, obesity and diabetes have been associated with a preponderance for small, dense LDL particles. Just as non-HDL-C is a better correlate of apoB than LDL-C, elevated non-HDL-C is associated with smaller LDL particle size while elevated LDL-C is not. Prospective cohort data from the Quebec Cardiovascular Study show that an increased risk of cardiovascular events is associated with a preferential accumulation of small dense LDL particles \<255A ([@b106], [@b105]). While LDL-C in patients who developed CAD was a mere 8% higher than those without disease, the increase in cholesterol carried in small LDL particles (\<255A) was 40% ([@b106]). As expected, individuals with a preferential accumulation of cholesterol in small dense LDL particles had higher BMI, elevated TG, lower HDL-C and higher insulin levels, which are all features of the metabolic syndrome ([@b105]). Conversely, the preferential accumulation of cholesterol in larger LDL particles (\>260A) was associated with a relatively reduced incidence of ischemic heart disease and fewer features of the metabolic syndrome ([@b105]). Similarly, in the Framingham cohort, LDL-C was not significantly different in men with and without the metabolic syndrome although those with the metabolic syndrome had a greater number of small LDL particles, a smaller average LDL size and greater apoB ([@b57]). While LDL particle size bears no correlation to LDL-C, patients with smaller LDL particles had higher TC, non-HDL-C and TG with lower HDL-C than those with larger LDL particle size ([@b53]). Similarly, data from the EPIC-Norfolk Prospective Population Study has shown non-HDL-C to correlate inversely with LDL particle size (p \< 0.01) while there was no correlation between LDL-C and LDL particle size (p = 0.6) ([@b29]). Given that determination of LDL size is not part of routine patient care and LDL-C levels are usually normal or mildly elevated in those with diabetes, an alternative to LDL-C to quantify risk appears to be warranted.

Non-HDL-C is superior to LDL-C in cardiovascular risk prediction
================================================================

While non-HDL-C has been correlated to cardiovascular events in epidemiologic studies ([@b59]; [@b85]; [@b74]; [@b14]), the purpose of this section is to describe studies that have compared the predictive value of non-HDL-C with LDL-C. Where data is available, the predictive value of non-HDL-C is also compared with apoB. While non-HDL-C levels have been associated with fatty streaks, vascular stenoses, angiographic progression of CAD, and carotid IMT ([@b10]), the linking of non-HDL-C to the hard clinical endpoint is of greater prognostic and therapeutic value and is crucial to effecting guideline change. Hence, this section only deals with studies that have reported hard clinical end points. These are summarized in [Table 2](#tbl2){ref-type="table"} and selected studies are discussed herein. To the author's knowledge, this is the most comprehensive assimilation of such studies.

###### 

A summary of studies that have compared non-HDL-C to either LDL-C or ApoB for prediction of cardiovascular events

  Population                                                                                                                                                                                                                                                                                                            N                                               End point                                                                                                Average follow up (years)                Type of analysis and reference (comparator) group for the cohort                                                                                                                                      HR (95% CI or p value)                                                                                                                                                                                                                                                              Reference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- -------------------------------------------------------------------------------------------------------- ---------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------
  Men and women in the Framingham cohort, Framingham Offspring cohort, Lipid Research Clinics Prevalence Study and the Multiple Risk Factor Intervention Trials; 5% diabetics; average BMI 26.0; average TG 157 mg/dl; average VLDL-C 29 mg/dl                                                                          19381; 18363 non-diabetics and 1018 diabetics   CAD death                                                                                                13                                       Multivariate; Comparator for analyses is non-diabetics with LDL-C \<100 mg/dl or non-diabetics with non-HDL-C\<130 mg/dl                                                                              DIABETICS Non-HDL-C\<130 mg/dl; 2.73 (1.27--5.87) Non-HDL-C 130--159 mg/dl; 2.73(1.60--4.66) Non-HDL-C \>160 mg/dl; 3.68 (2.51--5.39) NON-DIABETICS Non-HDL-C 130--159 mg/dl; 0.95(0.65--1.39) Non-HDL-C \>160 mg/dl; 2.11 (1.52--2.91)                                             DIABETICS LDL-C \<100 mg/dl; 4.63 (2.21--9.70) LDL-C 100--129 mg/dl; 2.93 (1.53--5.61) LDL-C\>130 mg/dl; 5.94 (3.64--9.69) NON-DIABETICS LDL-C 100--129 mg/dl; 1.73 (1.07--2.81) LDL-C\>130 mg/dl; 3.02(1.94--4.72)                                          NA                                                                                                                                                                                                                                                  [@b64]
  Women free of cardiovascular disease at baseline enrolled in the Women's Health Study; 3% diabetics; average BMI 26.3                                                                                                                                                                                                 15632                                           Cardiovascular death or non-fatal myocardial infarction, stroke or coronary revascularization.           10                                       Multivariate; in each analysis, the fifth quintile (Q5) is compared to the reference first quintile (Q1)                                                                                              Q5:Q1 (\>191 mg/dl versus \<123 mg/dl); 2.51 (1.69--3.72)                                                                                                                                                                                                                           Q5:Q1 (\>154 mg/dl versus \<98 mg/dl); 1.62 (1.17--2.25)                                                                                                                                                                                                     Q5:Q1 (\>126 mg/dl versus \<79 mg/dl); 2.50 (1.68--3.72)                                                                                                                                                                                            [@b88]
  Men and women free of CAD at baseline; Framingham cohort; 6.8% diabetics; average BMI 24; average TG 111mg/dl; average VLDL-C 25 mg/dl                                                                                                                                                                                5794                                            Fatal and non-fatal myocardial infarction, acute coronary insufficiency or sudden cardiovascular death   22                                       Multivariate; Comparator for LDL-C analysis is LDL-C \<130 mg/dl and for non-HDL-C\<160 mg/dl                                                                                                         Non-HDL-C 160--189 mg/dl; 1.64 (1.13--2.40) Non-HDL-C \>190 mg/dl; 2.21 (1.57--3.11) 1.008 per mg/dl TG \< 200 mg/dl (p \< 0.01) 1.006 per mg/dl TG\>200 mg/dl (p \< 0.01)                                                                                                          LDL-C 130--159 mg/dl; 1.50 (1.05--2.15) LDL-C\>160 mg/dl; 2.04 (1.44--2.90) 1.009 per mg/dl TG \< 200 mg/dl 1.004 per mg/dl TG\>200 mg/dl (p = NS)                                                                                                           NA                                                                                                                                                                                                                                                  [@b65]
  Patients enrolled in the SHEP trial; age\>60 with mean blood pressure 170/77 mmHg; 10% diabetics; average BMI 27.5; average TG 144 mg/dl; 13% on lipid-lowering therapy                                                                                                                                               4736                                            Non-fatal myocardial infarction, CAD death                                                               4.5                                      Multivariate; risk is expressed per 40 mg/dl increase in lipid parameters                                                                                                                             1.32 (1.13--1.54)                                                                                                                                                                                                                                                                   1.30 (1.09--1.54)                                                                                                                                                                                                                                            NA                                                                                                                                                                                                                                                  [@b39]
  Men and women free of cardiovascular disease at baseline; individuals enrolled in the Lipid research clinics prevalence program; 4% diabetics; average BMI 26.2; average TG 136 mg/dl; average VLDL-C 27 mg/dl; 2% on lipid-lowering therapy                                                                          4462                                            Cardiovascular death                                                                                     19                                       Corrected for age; comparator for LDL-C analysis is LDL-C \<130 mg/dl and for non-HDL-C\<160 mg/dl                                                                                                    30 mg/dl increments correspond to a 19% increase in cardiovascular death in men and 11% in women                                                                                                                                                                                    30 mg/dl increments correspond to a 15% increase in cardiovascular death in men and 8% in women                                                                                                                                                              NA                                                                                                                                                                                                                                                  [@b25]
  Chinese men and women free of cardiovascular disease at baseline; 13% diabetics; average BMI 23.5; average TG 127 mg/dl.                                                                                                                                                                                              3568                                            non-fatal myocardial infarction, fatal CAD or coronary revascularization                                 13.6                                     Multivariate; in each analysis, the fifth quintile (Q5) is compared to the reference first quintile (Q1)                                                                                              Q5:Q1; 1.98 (1.00--3.92)                                                                                                                                                                                                                                                            Q5:Q1; 1.86 (1.00--3.46)                                                                                                                                                                                                                                     Q5:Q1; 2.74 (1.45--5.19)                                                                                                                                                                                                                            [@b23]
  Men and women free of CAD at baseline; Framingham cohort; 4% diabetics. This Framingham cohort is different to that studied by Liu et al (13).                                                                                                                                                                        3322                                            myocardial infarction, angina pectoris, coronary insufficiency or cardiovascular death                   15                                       Multivariate; Hazard ratios expressed per increase in one standard deviation of the population. Analyses were stratified based on sex.                                                                MALE 1.22 (1.06--1.40) per one standard deviation increase FEMALE 1.28 (1.06--1.56) per one standard deviation increase                                                                                                                                                             MALE 1.11 (0.97--1.27) per one standard deviation increase FEMALE 1.20 (0.99--1.46) per one standard deviation increase                                                                                                                                      MALE 1.37 (1.20--1.57) per one standard deviation increase FEMALE 1.38 (1.15--1.67) per one standard deviation increase                                                                                                                             [@b54]
  1003 men and women with a CAD event and 1885 matched controls enrolled in the EPIC-Norfolk study designed to study determinants of cancer. Participants were apparently healthy and free of cardiovascular disease at baseline. 3% diabetics; average BMI 27; average TG 148 mg/dl; 0% using lipid-lowering therapy   2888                                            Hospital admission for CAD or death secondary to CAD.                                                    6 years follow up; case control design   Multivariate; in each analysis, the fourth quartile (Q4) is compared to the reference first quartile (Q1). This study reported odds ratio and not hazard ratios (HR)                                  Q4:Q1; 1.63(1.26--2.11)                                                                                                                                                                                                                                                             Q4:Q1; 1.55 (1.22--1.96)                                                                                                                                                                                                                                     NA                                                                                                                                                                                                                                                  [@b29]
  Men and women with myocardial infarction or angina pectoris enrolled in the placebo arm of the 4S study; TG \<220 mg/dl for enrolment;                                                                                                                                                                                2223                                            CAD death or non-fatal myocardial infarction                                                             5.4                                      Multivariate; data reported as relative risk reductions                                                                                                                                               16.4% risk reduction (p = 0.002) per 39 mg/dl decrease in non-HDL-C                                                                                                                                                                                                                 12.8% risk reduction (p = 0.024) per 39 mg/dl decrease in LDL-C                                                                                                                                                                                              5.3% risk reduction (p = 0.0025) per 10 mg/dl decrease in ApoB                                                                                                                                                                                      [@b81]
  Men and women with myocardial infarction or angina pectoris enrolled in the treatment arm (Simvastatin 20 or 40 mg; average 27 mg) of the 4S study; TG \<220 mg/dl for enrolment;                                                                                                                                     2221                                            CAD death or non-fatal myocardial infarction                                                             5.4                                      Multivariate; data reported as relative risk reductions. The absolute reductions in lipid parameters at one year post-randomization were assessed for prognostic significance over the study period   24.9% risk reduction (p = 0.002) per 39 mg/dl decrease in non-HDL-C 1.7% reduction in events (0.9--2.4) per 1% reduction in non-HDL-C                                                                                                                                               27.8% risk reduction (p = 0.024) per 39 mg/dl decrease in LDL-C 1.7% reduction in events (1.0--2.4) per 1% reduction in LDL-C                                                                                                                                8.8% risk reduction (p = 0.0025) per 10 mg/dl decrease in ApoB 1.1% reduction in events (0.3--1.8) per 1% reduction in ApoB                                                                                                                         [@b81]
  Diabetics free of cardiovascular disease at baseline from American Indian Communities (Strong Heart Study); 100% diabetics; average BMI 32; average TG 144 mg/dl;                                                                                                                                                     2108                                            Cardiovascular death or non-fatal CAD, myocardial infarction or stroke.                                  9                                        Multivariate; values of LDL-C or non-HDL-C were divided into tertiles and in each analysis, the third tertile (T3) is compared to the reference first tertile (T1)                                    T3:T1 (\>161mg/dl versus \<127 mg/dl); 2.23 (1.41--3.43) in men; 1.80 (1.32--2.46) in women T3:T1; 1.80 (1.27--2.54) TG\<150 mg/dl; 1.52 (1.12--2.07) TG\>150 mg/dl                                                                                                                 T3:T1 (\>115 mg/dl versus \<91mg/dl); 1.71 (1.17--2.48) in men; 1.61(1.19--2.17) in women T3:T1; 1.66 (1.17--2.34) TG\<150 mg/dl; 1.58 (1.16--2.16) TG\>150 mg/dl                                                                                            NA                                                                                                                                                                                                                                                  [@b69]
  Men of Japanese ancestry living in Oahu (The Honolulu Heart Study) free of CAD at baseline                                                                                                                                                                                                                            1751                                            Fatal CAD event or non-fatal myocardial infarction                                                       16                                       Multivariate; risk is expressed per 20 mg/dl increase in lipid parameters; stratified as middle aged (50--64 years old) or elderly (65--74 years old)                                                 MIDDLE AGE 1.18 (1.09--1.29) ELDERLY 1.30 (1.11--1.53)                                                                                                                                                                                                                              MIDDLE AGE 1.12 (1.02--1.23) ELDERLY 1.24 (1.05--1.48)                                                                                                                                                                                                       NA                                                                                                                                                                                                                                                  [@b87]
  Mediterranean men and women followed prospectively; 100% diabetics; average BMI 27; average TG 138 mg/dl                                                                                                                                                                                                              1565                                            Cardiovascular mortality                                                                                 11                                       Multivariate; analyses stratified based on age \<70 and \>70 years old comparator for LDL-C analysis is LDL-C \<111 mg/dl and for non-HDL-C\<137 mg/dl and for ApoB \<77 mg/dl                        AGE \<70 Non-HDL-C 137--163 mg/dl; 1.25 (0.54--2.87) Non-HDL-C 164--197 mg/dl; 1.47(0.69--3.12) Non-HDL-C \>198 mg/dl; 1.52 (0.72--3.23) AGE \>70 Non-HDL-C 137--163 mg/dl; 0.80 (0.53--1.19) Non-HDL-C 164--197 mg/dl; 0.80(0.54--1.19) Non-HDL-C \>198 mg/dl; 0.58 (0.36--0.93)   AGE \<70 LDL-C 111--136 mg/dl; 0.71 (0.31--1.63) LDL-C 137--165 mg/dl; 1.00(0.49--2.06) LDL-C \>166 mg/dl; 1.03 (0.52--2.08) AGE \>70 LDL-C 111--136 mg/dl; 0.96 (0.64--1.42) LDL-C 137--165 mg/dl; 0.84 (0.56--1.28) LDL-C \>166 mg/dl; 0.59 (0.38--0.95)   AGE \<70 ApoB 78--101 mg/dl; 1.33 (0.56--3.15) ApoB 101--126 mg/dl; 1.94(0.84--4.49) ApoB \>127 mg/dl; 2.86 (1.22--6.67) AGE \>70 ApoB 78--101 mg/dl; 1.18 (0.73--1.91) ApoB 101--126 mg/dl; 1.69(1.08--2.63) ApoB \>127 mg/dl; 1.50 (0.93--2.41)   [@b17]
  Patients enrolled in the BARI trial; all had multivessel CAD; 18% diabetics; average TG 184 mg/dl; 13% on lipid-lowering therapy                                                                                                                                                                                      1514                                            non-fatal myocardial infarction                                                                          5                                        Multivariate; risk is expressed per 10 mg/dl increase in lipid parameters                                                                                                                             1.049 (1.006--1.093)                                                                                                                                                                                                                                                                NS 1.033 (0.981--1.088)                                                                                                                                                                                                                                      NA                                                                                                                                                                                                                                                  [@b11]
  Diabetic cohort 16% with previous myocardial infarction; 100% diabetics; average BMI 29; average TG 230 mg/dl                                                                                                                                                                                                         1059                                            CAD death                                                                                                7                                        Multivariate;                                                                                                                                                                                         1.6 (1.2--2.3); for non-HDL-C \>200 mg/dl versus \<200 mg/dl;                                                                                                                                                                                                                       NS 1.3 (0.9--1.8); for LDL-C \>160 mg/dl versus \<160 mg/dl                                                                                                                                                                                                  NA                                                                                                                                                                                                                                                  [@b62]
  Diabetic women free of cardiovascular disease at baseline enrolled in the Nurses' Health study; 100% diabetics; average BMI 30; average TG 200 mg/dl; 4% using lipid-lowering therapy                                                                                                                                 921                                             Fatal CAD event, non-fatal myocardial infarction or coronary revascularization                           10                                       Multivariate; in each analysis, the fourth quartile (Q4) is compared to the reference first quartile (Q1). Non-HDL-C is even more predictive in those with TG\>200 mg/dl; discussed in text.          Q4:Q1 (quartile median 224 mg/dl versus 126 mg/dl); 1.97 (1.14--3.43)                                                                                                                                                                                                               Q4:Q1 (quartile median 179 mg/dl versus 98 mg/dl); 1.93 (1.15--3.22)                                                                                                                                                                                         Q4:Q1 (quartile median 131 mg/dl versus 74 mg/dl); 1.78 (1.02--3.11)                                                                                                                                                                                [@b94]
  Diabetic men free of cardiovascular disease at baseline enrolled in the health professionals' follow up study; 100% diabetics average BMI 27.1; average TG 182 mg/dl; 9% on lipid-lowering therapy                                                                                                                    746                                             Fatal CAD, non-fatal myocardial infraction, fatal stroke, non-fatal stroke, coronary revascularization   6                                        Multivariate; in each analysis the fourth quartile (Q4) is compared to the reference first quartile (Q1)                                                                                              Q4:Q1(\>195 mg/dl versus \<143 mg/dl); 2.25 (1.24--4.08)                                                                                                                                                                                                                            Q4:Q1(\>149 mg/dl versus \<102 mg/dl); NS 1.63 (0.94--2.81)                                                                                                                                                                                                  Q4:Q1(\>119 mg/dl versus \<89 mg/dl); 2.31 (1.25--4.27)                                                                                                                                                                                             [@b56]
  243 men with a CAD event enrolled in the Health professionals' follow up study and 496 matched controls; 6% diabetics; average BMI 25.8; average TG 130mg/dl; 0% on lipid-lowering therapy                                                                                                                            739                                             Fatal CAD or non-fatal myocardial infarction                                                             6 years follow up; case control design   Multivariate; in each analysis, the fifth quintile (Q5) is compared to the reference first quintile (Q1)                                                                                              Q5:Q1; 2.75 (1.62--4.67)                                                                                                                                                                                                                                                            Q5:Q1; 2.07 (1.24--3.45)                                                                                                                                                                                                                                     Q5:Q1; 2.98 (1.76--5.06)                                                                                                                                                                                                                            [@b83]
  100 patients with non-fatal myocardial infraction before the age of 36 and 100 matched controls (n = 100); 2% diabetics; average BMI 29; average TG 143 mg/dl                                                                                                                                                         200                                             Non-fatal myocardial infraction                                                                          Case control                             Multivariate; risk is expressed per 1 mg/dl increase in lipid parameters                                                                                                                              1.03 (1.01--1.05) per 1 mg/dl increase                                                                                                                                                                                                                                              1.02 (1.01--1.03) per 1 mg/dl increase                                                                                                                                                                                                                       1.02 (1.01--1.04) per 1 mg/dl increase                                                                                                                                                                                                              [@b86]

**Abbreviations:** BMI, body mass index; CAD, coronary artery disease; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; NS, not significant; NA, not available; HR, hazard ratio; TG, triglycerides.

In a 5794 patient cohort from Framingham who were initially free from CAD, VLDL-C predicted CAD events after adjustment for LDL-C ([@b65]). Further, within each LDL-C category (\<130 mg/dl, 130-159 mg/dl, \>160 mg/dl), non-HDL-C (\<160 mg/dl, 160-189 mg/dl, \>190 mg/dl) was additionally predictive of CAD event rates but within each non-HDL-C category, LDL-C was not predictive of event rates ([@b65]). As expected, LDL-C predicted CAD events in patients with TG \<200 mg/dl (RR 1.009 per mg/dl increase, p \< 0.01) as did non-HDL-C (RR1.008 per mg/dl increase, p \< 0.01). However, LDL-C lost predictive value in patients with TG \> 200 mg/dl while non-HDL-C remained predictive (RR1.006 per mg/dl increase, p \< 0.01) ([@b65]). Hence, non-HDL-C is a better predictor of CAD events and can be utilized 'across the board' regardless of TG. Interestingly, a study of diabetic women enrolled in the Nurses' Health study showed the predictive value of non-HDL-C to interact with TG. For the population as a whole (n = 921), the multivariate hazard ratio for a fourth:first quartile non-HDL-C value was 1.97 (p = 0.016) but in those with a TG \> 200 mg/dl, the hazard ratio for a fourth:first quartile non-HDL-C was 3.80 (p = 0.046) with a p for interaction of 0.045 ([@b94]). The confidence intervals for the hazard ratios were however wide and overlapping. Hence while available studies have suggested that non-HDL-C is predictive regardless of TG, of some concern are studies that have suggested that LDL-C loses predictive value in people with hypertriglyceridemia and this has been found in multiple studies. For instance, in a cohort from the Lipid Research Clinics prevalence study, increasing increments of non-HDL-C by 30 mg/dl were associated with an increasing risk of cardiovascular death ([@b25]) as outlined in [Table 2](#tbl2){ref-type="table"}. However, men with LDL-C \< 100 mg/dl, had an increased cardiovascular mortality when compared with men with LDL-C in the 100-130 mg/dl range. Careful analysis of the group of men with LDL-C \< 100 mg/dl showed the increased mortality to be confined to the group who also had TG \>200 mg/dl. Similarly, an analysis of diabetics (average TG 254 mg/dl) also suggests a dissociation between CAD death and LDL-C. Diabetics with LDL-C 100-129 mg/dl had a lower 13-year CAD mortality than diabetics with LDL-C \<100 mg/dl; however, the confidence intervals were wide ([@b64]). Given that hypertriglyceridemia affects 16% of the American population and 37% of diabetics ([@b95]), there is a potentially large population in which LDL-C does not reflect the risk of CAD events. Indeed, some analyses have suggested that TG can add prognostic information to LDL-C but not to non-HDL-C ([@b83]). Other studies have also compared the predictive value of non-HDL-C to apoB.

In 15,632 females followed in the Women's Health study, non-HDL-C and apoB were the strongest lipid measures associated with cardiovascular end points and these two measures were highly correlated (r = 0.87) (see [Table 2](#tbl2){ref-type="table"}) ([@b88]). ApoB was not superior to non-HDL-C in predicting cardiovascular events in this primary prevention, female cohort. Likewise, in a diabetic male cohort (n = 746) with high TG (average 182 mg/dl), apoB was not superior to non-HDL-C in predicting cardiovascular events ([@b56]). In contrast, other studies have suggested that apoB is a superior predictor of cardiovascular events than non-HDL-C ([@b83], [@b17], [@b23]) and a stronger correlate with markers of obesity ([@b92]). Further, apoB may be the superior risk marker in those aged \>70 years since there is a well described 'reverse epidemiology' that occurs in elderly populations whereby high lipids may be protective and hypocholesterolemia may represent a measure of frailty or selection bias ([@b17]).

Perspective
===========

While multiple prospective cohort studies show that non-HDL-C is superior to LDL-C in cardiovascular risk prognostication, to become the primary target of therapy non-HDL-C would also have to predict cardiovascular events in patients on statins. As shown in [Table 2](#tbl2){ref-type="table"}, the 4S investigators have shown non-HDL-C to predict cardiovascular events in patients using Simvastatin ([@b81]). Also, an analysis from the Greek Atorvastatin and Coronary Heart Disease evaluation (GREACE) study showed that the relative risk reduction of cardiovascular events in patients prescribed Atorvastatin was highly correlated with percentage reductions in non-HDL-C ([@b3]). Further, in this study, the percentage reduction in hard clinical endpoints correlated more strongly with reductions in non-HDL-C than LDL-C ([@b3]). Hence, the familiar linear relationship between relative risk reduction in CAD death or non-fatal myocardial infarction and LDL-C reduction with statins ([@b89]), if repeated with non-HDL-C may show stronger correlation and higher concordance. In this context, retrospective analyses of existing data and future inclusion of non-HDL-C as a primary outcome of lipid-lowering trials is strongly encouraged. The implications of such a shift in the primary target of therapy would probably mean intensification of lipid lowering therapy for patients with CAD or those who are at high risk for CAD. For instance, in the ACCESS program, patients with CAD had higher non-HDL-C (and ApoB) relative to LDL-C and since fewer patients reached non-HDL-C targets than LDL-C, the use of a non-HDL-C could conceivably lead to the appropriate intensification of therapy for a large number of patients ([@b5]). Data from the NCEP Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey also support the notion that the adoption of non-HDL-C would lead to the appropriate intensification of therapy in patients with CAD or its risk equivalents. For instance, the NEP-TUNE II survey reported that in the cohort of CAD patients with TG\>200 mg/dl, 57% were at the LDL-C goal of \<100 mg/dl while a mere 33% of patients achieved both LDL-C \<100 mg/dl and non-HDL-C \<130 mg/dl ([@b26]). Hence, the adoption of non-HDL-C as the primary target of therapy could have multiple advantages. Firstly, it is easier to calculate and its routine measurement is not limited to patients with TG\<400 mg/dl or fasting specimens ([@b52]). Secondly, it is superior to LDL-C in determining cardiovascular risk 'across the board'. Thirdly, its superiority over LDL-C seems to be especially pertinent to the obese, which is a considerable proportion of the world. Fourthly, it appears that non-HDL-C predicts events in patients on statin therapy although this point in particular requires further clarification. Without doubt, non-HDL-C will be the lipid target of the future. With time, the definition of obesity has evolved from an assessment of body mass to BMI to the current assessment with waist circumference. Similarly, the primary target of lipid lowering therapy will have to evolve in a society that is increasingly obese.
